Patient-Centric Mission. Asset-Centric Approach. We’re pursuing our Orexin Receptor 2 Agonist Program to bring potentially transformative treatment options to patients with sleep-wake, neurological, neurodegenerative and neuropsychiatric disorders.... Backed by Foresite Capital.
About the role
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Advanced degree (PhD, PharmD, or Master's) in health economics and outcomes research, pharmacoepidemiology, epidemiology, public health, health services research, health policy, pharmacy, or a related field
- 10+ years of relevant experience in health economics, outcomes research, epidemiology, or related disciplines within the pharmaceutical, biotechnology, healthcare, academic, or consulting sectors
- Experience designing and conducting studies using healthcare databases and other real-world data sources (claims, EHR, registries)
- Experience developing PRO strategies and/or RWE designs such as external or synthetic control arms
- Strong knowledge of the regulatory and payer landscape, including experience designing evidence strategies that meet payer and regulatory requirements for novel therapies
- Strong project management skills, with the ability to manage multiple projects and priorities in a matrixed organization
More about this role
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets with potential utility across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions.
Headquartered in Boston, Massachusetts, Centessa was recognized as a Great Place to Work ® in 2026.
Centessa is seeking a Director, Health Economics and Outcomes Research (HEOR) to lead the development and execution of HEOR strategies across the central disorders of hypersomnia portfolio. In this role you will lead robust evidence generation strategies that to deliver global and regional evidence to support regulatory requirements, HTA dossiers, and payer negotiations, for Centessa’s Orexin Franchise. Reporting to the Executive Director, HEOR, the, you will...
Browse similar: Startup jobs · Boston